Analyst Price Targets — FMS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 5, 2026 12:19 pm | — | Truist Financial | $28.00 | $23.51 | TheFly | Fresenius Medical price target raised to $28 from $26 at Truist |
| May 15, 2024 9:07 am | David MacDonald | Truist Financial | $24.00 | $22.48 | TheFly | Fresenius Medical price target raised to $24 from $21 at Truist |
| January 2, 2023 7:30 pm | James Vane-Tempest | Jefferies | $11.70 | $16.34 | TheFly | Fresenius Medical downgraded to Underperform from Buy at Jefferies |
| June 22, 2022 7:28 am | — | Truist Financial | $27.00 | $23.64 | Benzinga | Truist Securities Maintains Hold on Fresenius Medical Care, Lowers Price Target to $27 |
Latest News for FMS
FMS tops Q4 estimates as EPS jumps 59% and margins expand, powered by savings from its FME25+ program despite portfolio-optimization-driven sales pressure.
Fresenius Medical Care AG (FMS) Q4 2025 Earnings Call Transcript
Strong organic revenue growth1 in 2025 of 8% driven by all operating segments Driven by an exceptional Q4, full year operating income2 growth of 27% reached top end of financial outlook, resulting in a significant margin step up to 11.3% Reported operating income grew by 31%, reported net income3 by 82% Earnings per share2 (EPS) grew by 44%, supported by the accelerated share buyback program Dividend of EUR 1.49…
Shares in the dialysis specialist were down 7.1% in European midday trade, with the decline erasing gains since the start of 2026.
Fresenius Medical Care reported a sharp rise in fourth‑quarter operating income on Tuesday, helped by accelerating cost savings and favourable reimbursement effects.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for FMS.
Senate Trading
No Senate trades found for FMS.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.